Cubist Systematic Strategies’s 4D Molecular Therapeutics FDMT Stock Holding History

Cubist Systematic Strategies’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-84,172	Closed	-$272K	–	3136
2025 Q1	$272K	Sell	84,172 -364,659	-81%	-$1.72M	﹤0.01%	2418
2024 Q4	$2.5M	Buy	448,831 +428,285	+2,085%	+$3.36M	0.02%	1226
2024 Q3	$222K	Buy	+20,546	New	+$341K	﹤0.01%	2533
2023 Q3	–	Sell	-1	Closed	-$18	–	3523
2023 Q2	$18	Sell	1 -1,814	-100%	-$33.4K	﹤0.01%	3397
2023 Q1	$31.2K	Sell	1,815 -14,317	-89%	-$278K	﹤0.01%	3628
2022 Q4	$358K	Buy	+16,132	New	+$249K	﹤0.01%	3251
2022 Q3	–	Sell	-23,568	Closed	-$165K	–	4511
2022 Q2	$165K	Buy	+23,568	New	+$229K	﹤0.01%	3781
2022 Q1	–	Sell	-17,913	Closed	-$393K	–	3622
2021 Q4	$393K	Buy	+17,913	New	+$439K	﹤0.01%	2615

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's FDMT Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 84,172 shares — an estimated $272K sold.

Cubist Systematic Strategies first reported a position in FDMT in Q4 2021 and held it in 8 quarters. The position peaked at $2.5M in Q4 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

Cubist Systematic Strategies reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 84,172 4D Molecular Therapeutics shares in Q2 2025, an estimated $272K.
Cubist Systematic Strategies first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 8 quarters.
Cubist Systematic Strategies's 4D Molecular Therapeutics position peaked at $2.5M in Q4 2024.
120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.